Table 1.
Correlations between E2F7 expression and clinicopathological parameters.
| Characteristic | Low expression of E2F7 | High expression of E2F7 | p |
|---|---|---|---|
| n | 269 | 270 | |
| Age, n (%) | 0.322 | ||
| <=60 | 128 (23.7%) | 141 (26.2%) | |
| >60 | 141 (26.2%) | 129 (23.9%) | |
| Race, n (%) | 0.235 | ||
| Asian | 3 (0.6%) | 5 (0.9%) | |
| Black or African American | 34 (6.4%) | 23 (4.3%) | |
| White | 229 (43%) | 238 (44.7%) | |
| Gender, n (%) | 0.164 | ||
| Female | 101 (18.7%) | 85 (15.8%) | |
| Male | 168 (31.2%) | 185 (34.3%) | |
| T stage, n (%) | 0.008 | ||
| T1 | 151 (28%) | 127 (23.6%) | |
| T2 | 40 (7.4%) | 31 (5.8%) | |
| T3 | 76 (14.1%) | 103 (19.1%) | |
| T4 | 2 (0.4%) | 9 (1.7%) | |
| N stage, n (%) | 0.013 | ||
| N0 | 115 (44.7%) | 126 (49%) | |
| N1 | 2 (0.8%) | 14 (5.4%) | |
| M stage, n (%) | 0.007 | ||
| M0 | 222 (43.9%) | 206 (40.7%) | |
| M1 | 27 (5.3%) | 51 (10.1%) | |
| Pathologic stage, n (%) | 0.013 | ||
| Stage I | 149 (27.8%) | 123 (22.9%) | |
| Stage II | 33 (6.2%) | 26 (4.9%) | |
| Stage III | 58 (10.8%) | 65 (12.1%) | |
| Stage IV | 29 (5.4%) | 53 (9.9%) | |
| Histologic grade, n (%) | 0.015 | ||
| G1 | 9 (1.7%) | 5 (0.9%) | |
| G2 | 125 (23.5%) | 110 (20.7%) | |
| G3 | 105 (19.8%) | 102 (19.2%) | |
| G4 | 25 (4.7%) | 50 (9.4%) | |
| OS event, n (%) | 0.003 | ||
| Alive | 199 (36.9%) | 167 (31%) | |
| Dead | 70 (13%) | 103 (19.1%) | |
| DSS event, n (%) | < 0.001 | ||
| Alive | 226 (42.8%) | 194 (36.7%) | |
| Dead | 35 (6.6%) | 73 (13.8%) | |
| PFI event, n (%) | < 0.001 | ||
| Alive | 207 (38.4%) | 171 (31.7%) | |
| Dead | 62 (11.5%) | 99 (18.4%) |